Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lessons from the "Euro-Phospholipid" project.

Ricard Cervera1

  • 1Department of Autoimmune Diseases, Institut Clínic of Medicine and Dermatology, Hospital Clínic, Barcelona, Catalonia, Spain. rcervera@clinic.ub.es

Autoimmunity Reviews
|January 15, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence and prognostic value of activated protein C resistance and anti-protein C antibodies in patients with antiphospholipid antibodies: an APS ACTION Registry study.

Rheumatology (Oxford, England)·2026
Same author

Correction: Anti-β2GPI IgG display a broad reactivity against different β2GPI domains beyond domain 1: results from the APS ACTION and multi-center Italian cohorts.

Frontiers in immunology·2026
Same author

Hydroxychloroquine and teratogenic risk in pregnancy in systemic autoimmune diseases: A systematic narrative review.

Autoimmunity reviews·2026
Same author

Anti-β2GPI IgG display a broad reactivity against different β2GPI domains beyond domain 1: results from the APS ACTION and multi-center Italian cohorts.

Frontiers in immunology·2026
Same author

Changing Patterns in Hospitalisations of Patients with Systemic Lupus Erythematosus over Three Decades at a Tertiary Referral Centre in Catalonia.

Journal of clinical medicine·2026
Same author

Hydroxychloroquine as an Adjunct Therapy for Secondary Thrombosis Prevention in Primary Antiphospholipid Syndrome: A Systematic Review and Meta-analysis.

Rheumatology and therapy·2026
Same journal

Decoding gut microbiome alterations in celiac disease: Implications for pathogenesis and treatment.

Autoimmunity reviews·2026
Same journal

Rethinking immunosuppression in limited cutaneous systemic sclerosis. The lcSSc conundrum; pros and cons for a timely immunosuppressive treatment.

Autoimmunity reviews·2026
Same journal

Kidney failure in patients with ANCA-associated vasculitis: A systematic review of outcomes.

Autoimmunity reviews·2026
Same journal

The role of antimicrobial peptides in rheumatoid arthritis: From mucosal predisposition to chronic synovitis.

Autoimmunity reviews·2026
Same journal

The role of short-chain fatty acids as key mediators of gut microbiota - host crosstalk in thyroid diseases.

Autoimmunity reviews·2026
Same journal

Intermittent hydrarthrosis (periodic synoviosis): A narrative review.

Autoimmunity reviews·2026
See all related articles

The Euro-Phospholipid project studied 1000 antiphospholipid syndrome (APS) patients across Europe. It identified key clinical and immunological features, revealing distinct patient subgroups for better management.

Area of Science:

  • Rheumatology
  • Immunology
  • Clinical Epidemiology

Background:

  • Antiphospholipid syndrome (APS) is a complex autoimmune disorder with significant clinical heterogeneity.
  • Multicenter studies are crucial for understanding rare diseases like APS with diverse patient populations.
  • The European Forum on Antiphospholipid Antibodies facilitates collaborative research in APS.

Purpose of the Study:

  • To establish a large, prospective European cohort of patients with antiphospholipid syndrome (APS).
  • To identify the prevalence and characteristics of clinical and immunological manifestations of APS.
  • To explore the possibility of defining clinically significant, homogeneous APS patient subsets.

Main Methods:

  • Prospective, multicenter cohort study design.

Related Experiment Videos

  • Inclusion of 1000 patients diagnosed with antiphospholipid syndrome (APS).
  • Data collection from 13 European countries over an extended follow-up period.

    • Main Results:

    • The Euro-Phospholipid project successfully recruited and followed 1000 APS patients from 13 European countries.
    • Key clinical and immunological manifestations at onset and during APS evolution were identified.
    • Evidence suggests the existence of more homogeneous and clinically relevant APS patient subsets.

    Conclusions:

    • Large-scale, multicenter prospective studies are feasible and valuable for characterizing complex autoimmune diseases like APS.
    • The Euro-Phospholipid project provides a foundation for understanding APS heterogeneity.
    • Identifying distinct APS subsets can potentially lead to more targeted and effective patient management strategies.